ESPR — Esperion Therapeutics Share News
0.000.00%
Last trade - 00:00- $822.04m
- $1.21bn
- $403.14m
U.S. STOCKS ON THE MOVE-Intel, Schlumberger, FedEx
Esperion Therapeutics tumbles on $75 mln equity raise
Brief: Esperion Prices Public Offering Of 30 Million Shares At $2.50 Each
Brief: Esperion Announces Proposed Public Offering Of Common Stock
Esperion Therapeutics tumbles after stock offering launch
Esperion climbs after patent win over Dr. Reddy’s cholesterol drugs
Brief: Esperion Reaches Settlement Agreement With ANDA Filer
U.S. STOCKS ON THE MOVE-BILL Holdings, Jackson Financial, Wills Towers Watson
Esperion Therapeutics rises after partner Otsuka wins Japan approval for high cholesterol drug
Esperion Therapeutics rises after partner Otsuka wins Japan approval for high cholesterol drug
Brief: Otsuka Wins Japan Approval To Market Esperion’s Nexletol For Hypercholesterolemia Treatment
Brief: Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Esperion Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Esperion Therapeutics Q2 revenue up 12%, profit beats estimates
Esperion Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol
Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Esperion Therapeutics Q1 Basic EPS USD -0.21
Esperion Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview